Results 201 to 210 of about 174,147 (309)

Dermoscopy in Necrolytic Acral Erythema: A Case Report

open access: yesDermatology Practical & Conceptual
Shivani Bansal   +3 more
doaj   +1 more source

Line‐Field Confocal Optical Coherence Tomography: A Diagnostic Tool Facilitating the Diagnosis of Sweet's Syndrome. A Case Report

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Sweet's syndrome is a rare neutrophilic dermatosis characterized by an acute onset of erythematous and infiltrative lesions. Diagnosis is based on clinical, histopathological, and laboratory findings. We propose that non‐invasive skin imaging techniques, such as line‐field confocal optical coherence tomography (LC‐OCT), may be beneficial for ...
Aleksandra Anderson   +5 more
wiley   +1 more source

Eczema‐Like Amelanotic Melanoma: A Diagnostic Challenge

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Amelanotic melanoma (AM) is a rare and aggressive variant of cutaneous melanoma characterised by the absence of pigmentation, often leading to delayed diagnosis due to its ability to mimic benign inflammatory or neoplastic conditions. We report the case of a 68‐year‐old woman presenting with a slowly enlarging, erythematous, mildly scaling ...
Agata Janowska   +8 more
wiley   +1 more source

Persistent Lip Swelling Due to an Embedded Tooth Fragment Following Facial Trauma

open access: yes
JEADV Clinical Practice, EarlyView.
Jorge Valdespino‐Valdes   +4 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Topical Ruxolitinib in Adolescents With Vitiligo: A 52‐Week Retrospective Study

open access: yesJEADV Clinical Practice, EarlyView.
Topical ruxolitinib 1.5% cream was assessed in 39 adolescents with non‐segmental vitiligo. Median T‐VASI fell at week 24 (n = 34) and week 52 (n = 18), with repigmentation most pronounced on the face: 55.6% reached F‐VASI50 at week 52. Few adverse events were recorded, all mild application‐site reactions in 4 of 39 patients.
L. Coronella   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy